Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical guideline

AAN and AHS update migraine prevention guideline

Analysis based on 7 articles · First reported Aug 31, 2026 · Last updated Sep 08, 2026

Sentiment
10
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The guideline may increase prescription rates for migraine preventive medications, potentially benefiting pharmaceutical companies that manufacture these drugs. It also reinforces the clinical importance of newer treatment classes, possibly influencing market share and investment in migraine therapeutics.

Pharmaceuticals Healthcare

On August 31, 2026, the American Academy of Neurology (AAN) and the Headache (journal) (AHS) jointly published an updated clinical practice guideline on pharmacologic treatment for migraine prevention in adults. The guideline, which updates the 2012 version, appears in Neurology and Headache journals and is endorsed by the American Academy of Family Physicians. It provides evidence-based recommendations for both chronic and episodic migraine, incorporating newer preventive medications alongside established ones. The update emphasizes offering preventive treatment to adults with four or more migraine days per month or significant functional impairment, and encourages shared decision-making considering efficacy, side effects, cost, and comorbidities. The guideline was authored by experts including Tamara Pringsheim, Rebecca C. Burch, and others, and was funded by the AAN.

100 American Academy of Neurology issued guideline update
100 Headache (journal) issued guideline update
ngo
Co-issued the updated guideline, reinforcing its role as a leading authority in neurology and potentially increasing its influence and membership.
Importance 100.0 Sentiment 10.0
ngo
Co-issued the updated guideline, strengthening its position in headache medicine and promoting its mission.
Importance 100.0 Sentiment 10.0
ngo
Endorsed the guideline, which may guide family physicians in prescribing migraine preventives.
Importance 20.0 Sentiment 5.0
per
Guideline author who provided expert commentary on the update.
Importance 20.0 Sentiment 5.0
per
Guideline author who provided expert commentary on the update.
Importance 20.0 Sentiment 5.0
per
AAN President who commented on the guideline's importance.
Importance 10.0 Sentiment 5.0
per
AHS President who commented on the guideline's impact.
Importance 10.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.